CELL INTELLIGENCE · 肿瘤细胞治疗研究

为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？

Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?

用于 CAR-T 细胞快速床旁/体内编程的可注射生物指令性微泡沫

Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells.

大语言模型引导的 CAR-T 计算平台用于低抗原密度肝癌的细胞因子优化

Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density.

以实体瘤特征为门控的超声预处理引导 CAR-T 治疗

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy.

B7-H3 CAR-T 细胞根除肝内胆管癌并诱导持久缓解

B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.

这些结果为在晚期 ICC 患者的临床试验中评估 iCas9.B7-H3 CAR-T 细胞策略提供了有力依据。

肝细胞癌的嵌合抗原受体治疗

Chimeric antigen receptor therapy for hepatocellular carcinoma.

CAR-T 细胞疗法在肝细胞癌中的应用：从机制见解到临床转化

CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation.

rhIL-7-hyFc（一种长效白细胞介素-7）提升 CAR-T 细胞治疗实体瘤的疗效

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.

本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。

分泌抗 FAP/抗 CD3 分子的间皮素 CAR-T 细胞高效靶向胰腺导管腺癌及其基质

Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.

CAR-TEAM 细胞能够实现对肿瘤基质的修饰，从而导致 PDAC 肿瘤的清除增加。这种方法为胰腺癌提供了一种有前景的治疗选择。

利用 ADA1 和 CD26 对 CAR-T 细胞进行选择性能量补充增强抗肿瘤免疫

Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity.